FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018394017> ?p ?o ?g. }

• W2018394017 endingPage "888" @default.
• W2018394017 startingPage "880" @default.
• W2018394017 abstract "Patients with chronic hepatitis C genotype 1 (HCV-1) and difficult-to-treat characteristics respond poorly to pegylated interferon alfa and ribavirin (RBV), and could benefit from an interferon with increased activity (consensus interferon or CIFN), favorable viral kinetics from daily dosing, and a longer duration of therapy. The purpose of this pilot study was to determine the efficacy and safety of daily CIFN + RBV for initial treatment of patients with HCV-1 infection. Patients with difficult-to-treat characteristics (92% male, 33% African American, 78% Veterans Affairs [VA]; 67% high viral load, 59% stage 3–4 fibrosis, and mean weight of 204 lbs) were enrolled at seven VA and two community medical centers. They were randomized to daily CIFN (15 mcg/day SQ) and RBV (1–1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52–72 weeks (from time of viral response +48 weeks) (group B, n = 31). Intention to treat analysis for treatment groups A and B demonstrated 33% (11/33) and 32% (10/31) sustained virologic response (SVR), respectively. Only 2/31 patients in group B received more than 52 weeks of treatment. The overall group demonstrated a 31% (20/64) rapid virologic response rate (RVR), 54% (34/64) end of treatment virologic response and a 33% (21/64) SVR. Patients with RVR at 4 weeks, early virologic response from 8–12 weeks, and late virologic response from 16–24 weeks demonstrated SVR of 75% (15/20), 31% (4/13), and 22% (2/9), respectively. Overall early non-protocol discontinuation occurred in 26/64 (40%) patients. Daily CIFN and ribavirin for initial treatment of HCV-1 patients has potential for achieving a relatively high RVR rate, but discontinuations are frequent and successful use of this regimen is highly dependent on adequate patient support to maintain adherence." @default.
• W2018394017 created "2016-06-24" @default.
• W2018394017 creator A5005478706 @default.
• W2018394017 creator A5012844104 @default.
• W2018394017 creator A5018003242 @default.
• W2018394017 creator A5027250094 @default.
• W2018394017 creator A5035622716 @default.
• W2018394017 creator A5038605864 @default.
• W2018394017 creator A5045675210 @default.
• W2018394017 creator A5052890599 @default.
• W2018394017 creator A5056841616 @default.
• W2018394017 creator A5073702849 @default.
• W2018394017 creator A5074446717 @default.
• W2018394017 creator A5079616065 @default.
• W2018394017 creator A5089846828 @default.
• W2018394017 date "2011-01-11" @default.
• W2018394017 modified "2023-10-18" @default.
• W2018394017 title "U.S. Multicenter Pilot Study of Daily Consensus Interferon (CIFN) Plus Ribavirin for “Difficult-to-Treat” HCV Genotype 1 Patients" @default.
• W2018394017 cites W1587896012 @default.
• W2018394017 cites W1967829449 @default.
• W2018394017 cites W1978921727 @default.
• W2018394017 cites W1992690275 @default.
• W2018394017 cites W2002746052 @default.
• W2018394017 cites W2014639431 @default.
• W2018394017 cites W2024049300 @default.
• W2018394017 cites W2027545702 @default.
• W2018394017 cites W2034654277 @default.
• W2018394017 cites W2035906120 @default.
• W2018394017 cites W2036281098 @default.
• W2018394017 cites W2041220983 @default.
• W2018394017 cites W2043886637 @default.
• W2018394017 cites W2059196197 @default.
• W2018394017 cites W2064546869 @default.
• W2018394017 cites W2071586067 @default.
• W2018394017 cites W2075282196 @default.
• W2018394017 cites W2084047059 @default.
• W2018394017 cites W2111044696 @default.
• W2018394017 cites W2112876622 @default.
• W2018394017 cites W2114602148 @default.
• W2018394017 cites W2127685726 @default.
• W2018394017 cites W2136136441 @default.
• W2018394017 cites W2164674340 @default.
• W2018394017 cites W2315201676 @default.
• W2018394017 doi "https://doi.org/10.1007/s10620-010-1504-y" @default.
• W2018394017 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3041922" @default.
• W2018394017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21221804" @default.
• W2018394017 hasPublicationYear "2011" @default.
• W2018394017 type Work @default.
• W2018394017 sameAs 2018394017 @default.
• W2018394017 citedByCount "6" @default.
• W2018394017 countsByYear W20183940172012 @default.
• W2018394017 countsByYear W20183940172014 @default.
• W2018394017 countsByYear W20183940172015 @default.
• W2018394017 crossrefType "journal-article" @default.
• W2018394017 hasAuthorship W2018394017A5005478706 @default.
• W2018394017 hasAuthorship W2018394017A5012844104 @default.
• W2018394017 hasAuthorship W2018394017A5018003242 @default.
• W2018394017 hasAuthorship W2018394017A5027250094 @default.
• W2018394017 hasAuthorship W2018394017A5035622716 @default.
• W2018394017 hasAuthorship W2018394017A5038605864 @default.
• W2018394017 hasAuthorship W2018394017A5045675210 @default.
• W2018394017 hasAuthorship W2018394017A5052890599 @default.
• W2018394017 hasAuthorship W2018394017A5056841616 @default.
• W2018394017 hasAuthorship W2018394017A5073702849 @default.
• W2018394017 hasAuthorship W2018394017A5074446717 @default.
• W2018394017 hasAuthorship W2018394017A5079616065 @default.
• W2018394017 hasAuthorship W2018394017A5089846828 @default.
• W2018394017 hasBestOaLocation W20183940171 @default.
• W2018394017 hasConcept C126322002 @default.
• W2018394017 hasConcept C142462285 @default.
• W2018394017 hasConcept C203014093 @default.
• W2018394017 hasConcept C2522874641 @default.
• W2018394017 hasConcept C2776178377 @default.
• W2018394017 hasConcept C2776408679 @default.
• W2018394017 hasConcept C2776455275 @default.
• W2018394017 hasConcept C2776461080 @default.
• W2018394017 hasConcept C2777288759 @default.
• W2018394017 hasConcept C2780040827 @default.
• W2018394017 hasConcept C2909179924 @default.
• W2018394017 hasConcept C41260117 @default.
• W2018394017 hasConcept C71924100 @default.
• W2018394017 hasConcept C90924648 @default.
• W2018394017 hasConceptScore W2018394017C126322002 @default.
• W2018394017 hasConceptScore W2018394017C142462285 @default.
• W2018394017 hasConceptScore W2018394017C203014093 @default.
• W2018394017 hasConceptScore W2018394017C2522874641 @default.
• W2018394017 hasConceptScore W2018394017C2776178377 @default.
• W2018394017 hasConceptScore W2018394017C2776408679 @default.
• W2018394017 hasConceptScore W2018394017C2776455275 @default.
• W2018394017 hasConceptScore W2018394017C2776461080 @default.
• W2018394017 hasConceptScore W2018394017C2777288759 @default.
• W2018394017 hasConceptScore W2018394017C2780040827 @default.
• W2018394017 hasConceptScore W2018394017C2909179924 @default.
• W2018394017 hasConceptScore W2018394017C41260117 @default.
• W2018394017 hasConceptScore W2018394017C71924100 @default.
• W2018394017 hasConceptScore W2018394017C90924648 @default.
• W2018394017 hasIssue "3" @default.
• W2018394017 hasLocation W20183940171 @default.

• next